drugset
drugset / Trial / NCT06747273

Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Participants in the United States

NCT06747273 ↗

Phase 1 Terminated 4 enrolled Sarepta Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the safety of SRP-9004.

Timeline

Start
2025-01-09
Primary completion
2025-06-18
Completion
2025-06-18

Outcome

Outcome not reported

Stopped (Business): “Study is being terminated due to a business decision.”

Drugs

EvaluationDrugModalityDoseRoute
Subject SRP-9004 Unknown — Intravenous

Indications

autosomal recessive limb-girdle muscular dystrophy type 2D